Dividend compounder review

CRNX

Crinetics Pharmaceuticals Inc · NASDAQ · US

Healthcare · Biotechnology

Chart Factor Intelligence Back to Screener
Score28.50/100
Confidence78.00/100
DecisionInsufficient Data
RatingAvoid
Scoring

Quality breakdown

Dividend Reliability 0.0 / 25 Payment history, cuts, growth, and regularity.
Dividend Sustainability 7.0 / 20 Payout, free cash flow, dividend cover, and debt.
Business Quality 11.5 / 25 Scale, cash generation, growth, margins, and returns.
Valuation Discipline 3.0 / 15 Yield, P/E, and price stretch versus long-term trend.
Long-Term Trend 7.0 / 15 Trend line, long return history, and drawdown control.
Metrics

Dividend and business context

Dividend Years0
Dividend Yield0.00%
Payout Ratio0.0%
Dividend Cut 5YNo
Net Income$-465.3M
Free Cash Flow$-383.7M
FCF Covers DividendUnknown
Debt / Equity3.74
P/E-
Revenue Growth 5Y155.3%
Net Margin0.0%
ROE-39.2%
Price vs Trend-18.4%
3Y Return86.2%
5Y Return75.7%
CurrencyUSD
Warnings

Review flags

No usable dividend history found.
Free cash flow is negative.
Debt to equity is elevated at 3.74.
Dividend diary

Activity record

CRNX dividend review warning Warning · Warning

Debt to equity is elevated at 3.74.